Galmed Partners with Tel Aviv University to Evaluate Aramchol for Metastatic Brain Cancers

summarizeSummary

Galmed Pharmaceuticals announced a research collaboration with Tel Aviv University to evaluate its brain-penetrating SCD1 inhibitor, Aramchol, as a targeted therapy for metastatic brain cancers, building on recent formulation breakthroughs.

check_boxKey Events

• Collaboration Agreement Announced

  Galmed Pharmaceuticals entered a research collaboration agreement with Ramot at Tel Aviv University to evaluate its brain-penetrating SCD1 inhibitor, Aramchol, as a targeted therapy for metastatic brain cancers.

• Targeting Metastatic Brain Cancers

  The collaboration focuses on leveraging Aramchol's new brain-penetrating formulation to treat p53-deficient brain metastases, a condition with a very poor prognosis and high unmet medical need.

• Leveraging Recent Breakthrough

  This initiative directly follows the company's recent breakthrough in converting Aramchol into a brain-penetrant SCD1 inhibitor, positioning it for central nervous system (CNS) diseases.

• Preclinical Validation Strategy

  The partnership aims to translate genomic and metabolic insights from Tel Aviv University's research into a therapeutic strategy, validating Aramchol's efficacy in advanced 3D in vitro and in vivo preclinical models.

auto_awesomeAnalysis

This collaboration is a significant strategic move for Galmed, expanding the potential therapeutic applications of its lead compound, Aramchol, into a high-unmet-need area. Following the recent announcement on 2026-04-09 of a brain-penetrating formulation, this partnership with Tel Aviv University aims to validate Aramchol's efficacy in treating p53-deficient brain metastases. For a clinical-stage biopharmaceutical company with a small market capitalization, diversifying and expanding the pipeline for its core asset is crucial for long-term growth and investor confidence. This development could open new avenues for future clinical trials and potentially increase the drug's market value.